Generate Biomedicines, Inc.
GENB
$15.64
$0.614.06%
NASDAQ
| 06/30/2026 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -9.45% | -25.77% | |||
| Total Depreciation and Amortization | -1.50% | -2.69% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 24.95% | -32.23% | |||
| Change in Net Operating Assets | 85.46% | 92.18% | |||
| Cash from Operations | 27.92% | 8.32% | |||
| Capital Expenditure | 75.32% | 79.49% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | 113.37% | -122.17% | |||
| Cash from Investing | 112.82% | -122.60% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | 10.94% | 8.69% | |||
| Issuance of Common Stock | -99.89% | -68.12% | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -100.00% | 166.67% | |||
| Cash from Financing | -100.15% | -101.28% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | -165.37% | -253.98% | |||